1,721,052 research outputs found

    The Difficult Interpretation of GHB Values in Postmortem Samples: What Strategies Should Be Followed?

    No full text
    We have read with great interest the paper oh Ha et al. which focuses on the importance of multi-matrixanalysis in gammahydroxybutyrate (GilB) postmortem toxicology and the usefulness of vitreous humor and brain tissue to distinguish exogenous GHB exposure from endogenous production. We agree with the authors on the importance of multi-matrix analysis for GHiB postmortem analysis, as also reported elsewhere, which "should possibly include the comparison of various biological conventional and non conventional matrices for a proper assessment of each case". Nevertheless,there are some points in Ha et al.'s study worthy of attention that we wish to discuss

    Intensive and pharmacological care in times of COVID-19: a “special ethics” for emergency?

    Full text link
    Background: The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (ICU). Main text: Having to make such decisions certainly entails substantial difficulties, and that has led many health care professional to seek ethical guidance. The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has attempted to meet that growing need by a set of recommendations, applying “clinical soundness” as a beacon standard; that approach tends to prioritize patients with higher life expectancy, which could be characterized as a “moderately utilitarian” approach. Yet, such a selection has engendered daunting ethical quandaries. The authors believe it can only be warranted and acceptable if rooted in a transparent decision-making process and verifiable, reviewed criteria. Moreover, the authors have stressed how clinical experimentation in a pandemic setting is a subtext of great interest from an ethical perspective. In Italy, no drug therapy and trials were undertaken for COVID-19 patients for a rather long period of time. When the epidemic was already circulating, an intervention proved necessary on the system of administrative procedures, aimed at expediting the authorization and validation of protocols, then bogged down by bureaucracy. A new system has since been instituted by a government decree that was signed about one month after the first Covid-19 case was officially recorded in the country. Such a swift implementation, which took just a few weeks, is noteworthy and proves that clinical trials can be initiated in a timely fashion, even with a pandemic unfolding. The concerted, action of supportive care and RCTs is the only way to attain effective forms of treatments for COVID-19 and any other future outbreak. Conclusions: The authors have arrived at the conclusion that the most effective and ethically sound response on the part of any national health care system would be to adequately reconfigure its organizational mechanisms, by making clinical trials and all related administrative procedures consistent with the current state of emergency

    Molecular Insights on New Psychoactive Substances (NPSs)

    No full text
    Currently, more than 1000 molecules have been classified as New Psychoactive Substances (NPSs), and it is reported that, every year, this number increases with new classes of compounds and/or newer generations of NPS families [...

    Corrigendum to “Fatal inhalation of nitrogen inside a closed environment: toxicological issues about the cause of death” [Forensic Sci. Int. 302C (2019) 109871] (Forensic Science International (2019) 302, (S0379073819302865), (10.1016/j.forsciint.2019.06.029))

    No full text
    The authors regret that Dr. Alberto Amadasi and Dr. Alessio Battistini have been missed from the author list. The author list should have been as: Alfredo Fabrizio Lo Faroa, Alessio Battistinic, Filippo Pirania, Alberto Amadasic, Antonino Paratoreb, Adriano Tagliabraccia, Francesco Paolo Busardòa aSection of Legal Medicine, Università Politecnica delle Marche, Ancona, Italy biCTLab s.r.l. Spin-off of University of Catania, Catania, Italy cSezione di Medicina Legale e delle Assicurazioni – Dipartimento di Scienze Biomediche per la Salute – Università degli Studi di Milano The authors would like to apologise for any inconvenience caused
    corecore